$3.29
-0.17(-4.78%)
Mkt Cap $90M
$1.03
$5.46
52-Week Range
At a Glance
AI-generated8-K
On March 19, 2026, the Board of AN2 Therapeutics, Inc. approved a stock option repricing of all outstanding Eligible Options under the 2017 and 2022 Equity Incentive Plans to $3.91 per share, including options held by named executive officers and non-employee directors. This provides retention incentives without stock dilution or additional cash costs.$90M
Market Cap
—
Revenue
-$32M
Net Income
Employees22
Fundamentals
How The Business Makes Money
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001880438
ISINUS0373261058
CUSIP037326105
Phone650-331-9090
Address1800 El Camino Real, Menlo Park, CA, 94027, US
SEC EDGAR